A New Vision: VeonGen's Gene Therapy Shows Promise in Fight Against Inherited Blindness

MUNICH, Germany – March 25, 2026 – In a significant development for patients with a leading cause of inherited blindness, VeonGen Therapeutics today announced encouraging early results for its gene therapy candidate, VG801. The ongoing Phase 1/2 clinical trial for Stargardt disease, a progressive condition with no approved treatments, has shown that the therapy is not only well-tolerated but also yields consistent and sustained improvements in patients' vision.

These pivotal findings, which offer a beacon of hope to the thousands affected by the disease worldwide, are set to be detailed in an oral presentation at the prestigious 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May. The announcement underscores a period of rapid innovation in a field that has long awaited a breakthrough, combining advanced genetic engineering with novel methods for measuring real-world visual function.

For patients and families grappling with Stargardt disease, the news represents a potential turning point. "We are encouraged by VG801’s clinical progress and its upcoming oral presentation at ARVO 2026,” stated Dr. Caroline Man Xu, Co-founder and Chief Executive Officer of VeonGen Therapeutics, in the company's official press release. The progress of VG801 is not just a scientific achievement but a crucial step toward addressing a critical unmet medical need.

Addressing a Root Cause of Blindness

Stargardt disease is the most common inherited retinal disorder, affecting approximately one in every 8,000 to 10,000 people. Caused by mutations in the ABCA4 gene, the disease typically begins in childhood or adolescence, leading to progressive loss of central vision. This impairs crucial daily activities like reading, recognizing faces, and driving, often culminating in legal blindness. To date, patient care has been limited to supportive measures, such as using low-vision aids and avoiding bright sunlight and vitamin A supplements, which can accelerate retinal damage.

The challenge for medicine has been to correct the faulty ABCA4 gene. VG801 is designed to do just that. The therapy aims to deliver a full-length, functional copy of the ABCA4 gene directly to the photoreceptor cells in the retina. In the first-in-human trial, which includes both adult and pediatric patients, the therapy has demonstrated a favorable safety profile with no serious adverse events reported. More importantly, preliminary efficacy data from patients followed for six and even twelve months show consistent functional improvements in best-corrected visual acuity (BCVA)—the standard eye chart test—and in a novel Virtual Reality Visual Test (VRVT).

Overcoming Gene Therapy's 'Large Gene' Hurdle

The scientific innovation behind VG801 lies in how it overcomes a fundamental limitation in gene therapy. The functional ABCA4 gene is approximately 7 kilobases (kb) in size, which is too large to fit inside a single adeno-associated virus (AAV), the most commonly used viral vector for delivering genetic material, which has a packaging capacity of about 4.7 kb. This size constraint has long been a major roadblock for treating Stargardt and other diseases caused by large genes.

VeonGen's solution is a dual-AAV vector system enabled by its proprietary vgRNA REVeRT large-gene delivery platform. This sophisticated approach splits the ABCA4 gene into two separate AAV vectors. When both vectors are co-delivered to the target retinal cells, their genetic payloads are designed to reconstitute the full-length functional ABCA4 protein. This allows the cells to begin producing the protein they need to function correctly, potentially halting or even reversing disease progression.

VeonGen is not alone in pursuing this strategy, highlighting its importance in the field. Companies like SpliceBio and AAVantgarde Bio are also advancing their own dual-AAV therapies for Stargardt disease. Other competitors are exploring different modalities, such as RNA editing therapies from Ascidian Therapeutics, which aim to correct the genetic defect at the RNA level, and oral medications like Alkeus Pharmaceuticals' gildeuretinol, which seeks to slow the buildup of toxic byproducts in the retina. This competitive landscape underscores the intensity of the race to find the first effective treatment for this devastating disease.

Regulatory Innovation and a Path to Patients

Beyond the scientific advances, the story of VG801 is also one of regulatory innovation. The therapy has received multiple key designations from the U.S. Food and Drug Administration (FDA) that could significantly shorten its path to approval. VG801 holds Regenerative Medicine Advanced Therapy (RMAT) designation, a program designed for therapies that show potential to address unmet medical needs for serious conditions. RMAT provides all the benefits of Breakthrough Therapy and Fast Track designations, including more intensive FDA guidance and the potential for accelerated approval.

Perhaps most notably, VG801 and its accompanying Virtual Reality Visual Test (VRVT) have been accepted into the FDA's Rare Disease Endpoint Advancement (RDEA) pilot program. This program is designed to support the development of novel endpoints for measuring efficacy in rare disease trials. Traditional endpoints like the BCVA eye chart may not fully capture the functional impact of a disease like Stargardt, which primarily affects central vision. The VRVT, developed to assess vision in a more dynamic, real-world simulated environment, could provide a more meaningful measure of how a therapy impacts a patient's quality of life. Its inclusion in the RDEA program signals the FDA's willingness to embrace innovative tools that can better demonstrate a drug's clinical benefit, potentially setting a new precedent for future ophthalmology trials.

With strong early data, a clever technological solution to a major biological challenge, and a clear, accelerated regulatory pathway, VeonGen is positioning itself as a formidable player in the ophthalmic gene therapy space. The company's focus remains on advancing VG801 toward a pivotal trial, while also exploring strategic partnerships to leverage its proprietary technology platforms in other therapeutic areas.